Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen

    loading  Checking for direct PDF access through Ovid


BackgroundThe prognosis of patients with advanced neuroblastoma (NB) remains poor. Major and early responses have an important bearing on treatment outcome. Iodine-131-metaiodobenzylguanidine (131I-MIBG) has the potential to deliver large doses of radiation specifically to NB cells. We evaluated the toxicity of, and response to, a novel induction regimen that included 131I-MIBG combined with cisplatin, cyclophosphamide, etoposide, vincristine, and doxorubicin.ProcedureThirteen children over 1 year of age with advanced NB at diagnosis were investigated extensively. 131I-MIBG was administered on day 10; this was preceded by chemotherapy in the five patients in group 1 (described in our previous study), and both preceded and followed by chemotherapy in the eight patients in group 2. The final induction regimen (used for group 2) lasted 1 month. Evaluation was performed 40 days after the start of treatment.ResultsIn both groups 1 and 2, the extent of hematologic toxicity, which was the only side effect, was similar to that seen with chemotherapy alone. Doses of 131I-MIBG as high as 16.6 mCi/kg showed no evidence of toxicity, even in patients with extensive bone marrow infiltration. Overall, we recorded two patients with a complete response (CR), six very good partial responses (VGPR), four partial responses (PR), and one mixed response (MR). In group 2, CR/VGPR were observed in patients treated with higher doses of 131I-MIBG.ConclusionsThe results of this pilot study show that 131I-MIBG, in combination with chemotherapy, appears to play an important role in a new and effective induction regimen for advanced NB. Pediatr Blood Cancer 2011;56:1032–1040. © 2011 Wiley-Liss, Inc.

    loading  Loading Related Articles